Omalizumab: Evidence for clinical benefits in different disorders

Strong evidence of benefit*:

Moderate-to-severe allergic asthma (patients greater than 6 years of age)

Chronic spontaneous urticaria (patients greater than 12 years of age)

Chronic rhinosinusitis with nasal polyposis (patients greater than 18 years of age)

Good evidence of benefit:

Chronic inducible urticaria

Allergic rhinitis

Food allergy

Protection from systemic allergic reactions during aeroallergen, venom, or food immunotherapy

Protection from systemic allergic reactions during drug desensitization

Viral-induced asthma exacerbations

Some evidence of benefit:

Nonallergic asthma

Mast cell activation disorders

Atopic dermatitis

* Disorders for which omalizumab is approved by the US Food and Drug Administration.

Graphic 104454 Version 4.0